BioSpace News Archive

Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates

Corindus, a Siemens Healthineers company and a leading developer of precision vascular robotics, announced today it has completed the first multi-city, transcontinental percutaneous coronary intervention (PCI) simulations in the United States over three network connection types – 5G wireless, dedicated fiber, and commercial public internet networks.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), today announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX‑102) for the treatment of Fabry disease.

Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices (QAPs™) that help ensure test accuracy, announces it has been awarded the “Beyond Borders” Ontario Business Achievement Award (OBAA) for 2019 by the Ontario Chamber of Commerce (OCC).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001.

UAVenture Capital Fund, a Tucson-based venture capital fund dedicated to the commercialization of University of Arizona discoveries, products, technologies and services, announced its thirteenth investment.

Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that reimbursement will be provided to PIFELTRO® and DELSTRIGO®, a once-daily NNRTI regimen for the treatment of HIV-1 infection, effective October 31st for the Ontario Drug Benefit Program and November 14th for la Régie de l’assurance maladie du Québec, RAMQ.

Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has reached an agreement to acquire Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform

Lavie Bio (Lavie), a subsidiary of Evogene (NASDAQ: EVGN) (TASE: EVGN), aiming to improve food quality, sustainability and agriculture productivity through the introduction of microbiome based ag-biological products, announces today phase advancement in its product development pipeline for wheat bio-stimulants

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the PCG Spotlight Series Conference taking place on Thursday, November 21, 2019 at the Harvard Club, 35 West 44th Street, NYC at 2:30 pm EST.